Predictive modeling of COPD exacerbation rates using baseline risk factors

Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221107314. doi: 10.1177/17534666221107314.

Abstract

Background: Demographic and disease characteristics have been associated with the risk of chronic obstructive pulmonary disease (COPD) exacerbations. Using previously collected multinational clinical trial data, we developed models that use baseline risk factors to predict an individual's rate of moderate/severe exacerbations in the next year on various pharmacological treatments for COPD.

Methods: Exacerbation data from 20,054 patients in the ETHOS, KRONOS, TELOS, SOPHOS, and PINNACLE-1, PINNACLE-2, and PINNACLE-4 studies were pooled. Machine learning was used to identify predictors of moderate/severe exacerbation rates. Important factors were selected for generalized linear modeling, further informed by backward variable selection. An independent test set was held back for validation.

Results: Prior exacerbations, eosinophil count, forced expiratory volume in 1 s percent predicted, prior maintenance treatments, reliever medication use, sex, COPD Assessment Test score, smoking status, and region were significant predictors of exacerbation risk, with response to inhaled corticosteroids (ICSs) increasing with higher eosinophil counts, more prior exacerbations, or additional prior treatments. Model fit was similar in the training and test set. Prediction metrics were ~10% better in the full model than in a simplified model based only on eosinophil count, prior exacerbations, and ICS use.

Conclusion: These models predicting rates of moderate/severe exacerbations can be applied to a broad range of patients with COPD in terms of airway obstruction, eosinophil counts, exacerbation history, symptoms, and treatment history. Understanding the relative and absolute risks related to these factors may be useful for clinicians in evaluating the benefit: risk ratio of various treatment decisions for individual patients.Clinical trials registered with www.clinicaltrials.gov (NCT02465567, NCT02497001, NCT02766608, NCT02727660, NCT01854645, NCT01854658, NCT02343458, NCT03262012, NCT02536508, and NCT01970878).

Keywords: ICS/LAMA/LABA; chronic obstructive pulmonary disease; exacerbations; machine learning; prediction model; triple therapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Disease Progression*
  • Female
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Pulmonary Disease, Chronic Obstructive* / drug therapy
  • Randomized Controlled Trials as Topic
  • Risk Factors

Associated data

  • ClinicalTrials.gov/NCT02497001
  • ClinicalTrials.gov/NCT02766608
  • ClinicalTrials.gov/NCT03262012
  • ClinicalTrials.gov/NCT01854645
  • ClinicalTrials.gov/NCT02536508
  • ClinicalTrials.gov/NCT02465567
  • ClinicalTrials.gov/NCT02343458
  • ClinicalTrials.gov/NCT01970878
  • ClinicalTrials.gov/NCT01854658
  • ClinicalTrials.gov/NCT02727660